Please login to the form below

Not currently logged in
Email:
Password:

EUSA founder joins Oxford BioTherapeutics as chairman

Bryan Morton has rich experience in oncology

Oxford Biotherapeutics Bryan MortonOncology-focused biotech Oxford BioTherapeutics has appointed industry veteran Bryan Morton as non-executive chairman.

Morton has 30 years' experience in the life sciences industry, including founding and serving as CEO of oncology specialist EUSA Pharma. This company was later sold to Jazz Pharma in 2012 for $700m.

Prior to founding EUSA in 2005, Morton founded Zeneus Pharma in 2003, before selling the company to Cephalon for $360m.

In addition to his entrepreneurial activities, Morton served as president of Convatec EMEA and spent more than 20 years in various roles at Merck & Co.

“His success in building valuable businesses and knowledge of the cancer space in particular will be important as we look to further develop our pipeline of antibody based cancer medicines to fulfil unmet patient needs,” said Christian Rohlff, CEO and founder of Oxford BioTherapeutics.

28th June 2013

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics